Vision

We are dedicated to improving the lives of patients with heart failure. 

Our vision is to lead the development of novel genetic medicines that promote angiogenesis to restore blood flow and function in failing hearts ("literally rewiring the heart"). We are committed to advancing genetic medicines in cardiology and bringing forward transformative solutions that tackle one of today’s greatest unmet medical and economic challenges: heart failure.

Scientific founder, Melanie Hulshoff PhD brings expertise in epigenetics and endothelial plasticity in cardiac fibrosis to develop RNA-based treatments for patients with heart failure.

RemiRe Therapeutics holds an exclusive license to advance the proprietary technology supporting the development of its gene therapy.

RemiRe Therapeutics is established in the Netherlands early 2025.